

Supplementary Table 2. Comparison of clinical outcome measures according to VAT, SAT, and SMA in patients with AAV

Clinical outcome	VAT (n = 117)			SAT (n = 117)			SMA (n = 117)		
	High (n = 58)	Low (n = 59)	p value	High (n = 58)	Low (n = 59)	p value	High (n = 58)	Low (n = 59)	p value
Mortality (+)	13 (22.4)	2 (3.4)	0.002	8 (13.8)	7 (11.9)	0.756	9 (15.5)	6 (10.2)	0.389
Mortality (-)	45 (77.6)	57 (96.6)		50 (86.2)	52 (88.1)		49 (84.5)	53 (89.8)	
ESRD (+)	8 (13.8)	12 (20.3)	0.349	5 (8.6)	15 (25.4)	0.016	13 (22.4)	7 (11.9)	0.131
ESRD (-)	50 (86.2)	47 (79.7)		53 (91.4)	44 (74.6)		45 (77.6)	52 (88.1)	
Disease relapse (+)	18 (31.0)	16 (27.1)	0.642	17 (29.3)	17 (28.8)	0.953	12 (20.7)	22 (37.3)	0.049
Disease relapse (-)	40 (69.0)	43 (72.9)		41 (70.7)	42 (71.2)		46 (79.3)	37 (62.7)	
Acute coronary syndrome (+)	2 (3.4)	2 (3.4)	0.999	2 (3.4)	2 (3.4)	0.999	2 (3.4)	2 (3.4)	0.999
Acute coronary syndrome (-)	56 (96.6)	57 (96.6)		56 (96.6)	57 (96.6)		56 (96.6)	57 (96.6)	
Stroke (+)	4 (6.9)	3 (5.1)	0.717	4 (6.9)	3 (5.1)	0.717	3 (5.2)	4 (6.8)	0.999
Stroke (-)	54 (93.1)	56 (94.9)		54 (93.1)	56 (94.9)		55 (94.8)	55 (93.2)	

Values are expressed as number (%).

VAT, visceral adipose tissue; SAT, subcutaneous adipose tissue; SMA, skeletal muscle area; AAV, anti-neutrophil cytoplasmic antibody-associated vasculitis; ESRD, end-stage renal disease.